You mentioned in your presentation the issue over intimidation, feeling that if your country goes first, you could have repercussions from pharmaceutical companies. You mentioned the situation in Indonesia.
We also had that situation during the last go-round here, when Bayer contacted me to lobby to get Avelox off the schedule list, because we'd decided to go the route of a schedule list of treatments available.
Can you describe greater the concern about setting a standard or precedent that could then be used against a country later? The repercussions probably go well beyond even just HIV and AIDS medications. There are probably other medications they're concerned about being shut out from their citizens.